Skip to main content
NCBI home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1985 Dec;20(6):703–706. doi: 10.1111/j.1365-2125.1985.tb05134.x

Antipyrine clearance and metabolite formation in children with congenital adrenal hyperplasia.

M W Teunissen, G J Bruining, B M De Jongh, E W Tenkate-Westerhof, D D Breimer
PMCID: PMC1400822  PMID: 4092001

Abstract

Antipyrine salivary clearance and half-life and the rate of formation of three principal metabolites of antipyrine (4-hydroxyantipyrine, 3-hydroxymethylantipyrine and norantipyrine) were assessed in nine children with congenital adrenal hyperplasia, six of whom were salt-losers and three of whom were non-salt-losers. No differences were found in comparison with data obtained in normal children.

Full text

PDF
703

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Breimer D. D. Interindividual variations in drug disposition. Clinical implications and methods of investigation. Clin Pharmacokinet. 1983 Sep-Oct;8(5):371–377. doi: 10.2165/00003088-198308050-00001. [DOI] [PubMed] [Google Scholar]
  2. Buchanan N., Davis M., Danhof M., Breimer D. D. Antipyrine metabolite formation in children in the acute phase of malnutrition and after recovery. Br J Clin Pharmacol. 1980 Oct;10(4):363–368. doi: 10.1111/j.1365-2125.1980.tb01772.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Danhof M., Idle J. R., Teunissen M. W., Sloan T. P., Breimer D. D., Smith R. L. Influence of the genetically controlled deficiency in debrisoquine hydroxylation on antipyrine metabolite formation. Pharmacology. 1981;22(6):349–358. doi: 10.1159/000137515. [DOI] [PubMed] [Google Scholar]
  4. Danhof M., Verbeek R. M., van Boxtel C. J., Boeijinga J. K., Breimer D. D. Differential effects of enzyme induction on antipyrine metabolite formation. Br J Clin Pharmacol. 1982 Mar;13(3):379–386. doi: 10.1111/j.1365-2125.1982.tb01389.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Dupont B., Oberfield S. E., Smithwick E. M., Lee T. D., Levine L. S. Close genetic linkage between HLA and congenital adrenal hyperplasia (21-hydroxylase deficiency). Lancet. 1977 Dec 24;2(8052-8053):1309–1312. doi: 10.1016/s0140-6736(77)90362-2. [DOI] [PubMed] [Google Scholar]
  6. Eichelbaum M. Defective oxidation of drugs: pharmacokinetic and therapeutic implications. Clin Pharmacokinet. 1982 Jan-Feb;7(1):1–22. doi: 10.2165/00003088-198207010-00001. [DOI] [PubMed] [Google Scholar]
  7. Idle J. R., Smith R. L. Polymorphisms of oxidation at carbon centers of drugs and their clinical significance. Drug Metab Rev. 1979;9(2):301–317. doi: 10.3109/03602537908993896. [DOI] [PubMed] [Google Scholar]
  8. Lu A. Y., West S. B. Multiplicity of mammalian microsomal cytochromes P-45. Pharmacol Rev. 1979 Dec;31(4):277–295. [PubMed] [Google Scholar]
  9. Nelson E. B., Bryan G. T. Steroid hydroxylations by human adrenal cortex microsomes 1, 2. J Clin Endocrinol Metab. 1975 Jul;41(1):7–12. doi: 10.1210/jcem-41-1-7. [DOI] [PubMed] [Google Scholar]
  10. Penno M. B., Vesell E. S. Monogenic control of variations in antipyrine metabolite formation. New polymorphism of hepatic drug oxidation. J Clin Invest. 1983 Jun;71(6):1698–1709. doi: 10.1172/JCI110924. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Rifkind A. B., Saenger P., Levine L. S., Pareira J., New M. I. Effects of growth hormone on antipyrine kinetics in children. Clin Pharmacol Ther. 1981 Jul;30(1):127–132. doi: 10.1038/clpt.1981.137. [DOI] [PubMed] [Google Scholar]
  12. Teunissen M. W., Meerburg-van der Torren J. E., Vermeulen N. P., Breimer D. D. Automated high-performance liquid chromatographic determination of antipyrine and its main metabolites in plasma, saliva and urine, including 4,4'-dihydroxyantipyrine. J Chromatogr. 1983 Dec 9;278(2):367–378. [PubMed] [Google Scholar]
  13. Teunissen M. W., Spoelstra P., Koch C. W., Weeda B., van Duyn W., Janssens A. R., Breimer D. D. Antipyrine clearance and metabolite formation in patients with alcoholic cirrhosis. Br J Clin Pharmacol. 1984 Nov;18(5):707–715. doi: 10.1111/j.1365-2125.1984.tb02533.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Toverud E. L., Boobis A. R., Brodie M. J., Murray S., Bennett P. N., Whitmarsh V., Davies D. S. Differential induction of antipyrine metabolism by rifampicin. Eur J Clin Pharmacol. 1981;21(2):155–160. doi: 10.1007/BF00637517. [DOI] [PubMed] [Google Scholar]
  15. Vesell E. S. Genetic and environmental factors affecting drug disposition in man. Clin Pharmacol Ther. 1977 Nov;22(5 Pt 2):659–679. doi: 10.1002/cpt1977225part2659. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES